October 20, 2025
In a significant stride towards enhancing ophthalmic care, Glaukos Corporation (NYSE: GKOS), a leading player in the medical technology and pharmaceutical landscape, recently announced the FDA s approval of its New Drug Application (NDA) for Epioxa, a cutting-edge treatment designed for corneal cross-linking in patients with keratoconus. This approval marks an important milestone for Glaukos, underscoring its commitment to developing innovative therapies that address serious visual impairments. The Epioxa BreakthroughEpioxa is poised to revolutionize the management of keratoconus, a rare but sight-threatening condition that affects the cornea s shape, leading to significant visual distortion and potential bl...
October 16, 2024
Glaukos Corporation Breaks New Ground in Ophthalmic Treatment with Epioxa In a significant advancement for the treatment of keratoconus, Glaukos Corporation (NYSE: GKOS) has announced highly encouraging topline results from its second Phase 3 confirmatory pivotal trial for Epioxa (Epi-on). This next-generation corneal cross-linking iLink therapy has successfully met its primary efficacy endpoint, underscoring the potential for Epioxa to transform treatment protocols for patients suffering from this debilitating eye condition. Successful Phase 3 Trial OutcomesThe results of the Phase 3 trial, revealed by Glaukos, demonstrate not only the efficacy of Epioxa in halting disease progression but also a favorable s...
June 14, 2024
Glaukos Corporation s Strategic Exchange Agreements Pave the Path for Growth and SuccessALISO VIEJO, Calif. - Glaukos Corporation (NYSE: GKOS), the renowned ophthalmic pharmaceutical and medical technology company, has recently taken a significant step towards strengthening its financial position and unlocking further opportunities for growth. The company has announced the execution of privately negotiated exchange agreements, whereby certain holders of its 2.75% Convertible Senior Notes due 2027 will exchange their existing notes for common stock. This transformative move, subject to customary closing conditions, will allow Glaukos to repurchase an impressive aggregate of $230 million principal amount of no...
Glaukos Corporation Receives FDA Approval for iDose TR, Presenting Positive Growth Prospects in the Glaucoma Market Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, has recently announced the approval of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA). This regulatory clearance allows Glaukos to introduce iDose TR, a single administration per eye of travoprost intracameral implant, into the market. The primary indication for iDose TR is the reduction of intraocular pressure (IOP) in patients suffering from glaucoma, a condition characte...
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Alcon Inc's business model revolves around providing advanced eye care products and services, including pharmaceuticals, surgical equipment, and vision care solutions.
Eyepoint Pharmaceuticals Inc is a pharmaceutical company that operates on a specialty business model focused on advancing ophthalmic therapies. They develop and commercialize innovative treatments using their proprietary drug delivery technology, allowing for sustained release of drugs to the eye. By leveraging their expertise in ophthalmology and controlled release technology, Eyepoint aims to improve patient outcomes and address unmet medical needs in eye care.
Sight Sciences Inc operates using a business model focused on developing and commercializing innovative medical devices and technologies for the treatment of ophthalmic diseases. They aim to improve patient outcomes and provide value to healthcare providers by constantly advancing their product portfolio and expanding their reach in the ophthalmology market.
Sources:
Glaukos Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Glaukos Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
